Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEn1E-1124 in healthy volunteers
NCT04728061Phase 1Completed
- Sponsor
- GEn1E Lifesciences
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GEN-1124 in acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) (2 arms), sponsored by GEn1E Lifesciences. Primary endpoint: Incidence of adverse events. Started Jan 2021; status: completed.
02
Drugs
GEN-1124
03
Conditions
acute respiratory distress syndrome (ARDS)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04728061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728061.